Skip to main content
Trials logoLink to Trials
. 2021 Mar 5;22:187. doi: 10.1186/s13063-021-05153-4

Correction to: Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial

Iwein Gyselinck 1,, Laurens Liesenborghs 1, Ewout Landeloos 1, Ann Belmans 2, Geert Verbeke 2, Peter Verhamme 1, Robin Vos 1, W Janssens 1; on behalf of the DAWn-Azithro consortium
PMCID: PMC7933907  PMID: 33673831

Correction to: Trials 22, 126 (2021)

https://doi.org/10.1186/s13063-021-05033-x

Following publication of the original article [1], we were notified of a typo in one of the authors’ names.

Originally published author name: Laurens Liesenborgs.

Corrected author name: be Laurens Liesenborghs.

The original article has been corrected.

Reference

  • 1.Gyselinck I, et al. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial. Trials. 2021;22:126. doi: 10.1186/s13063-021-05033-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Trials are provided here courtesy of BMC

RESOURCES